All In Biotech

NDA 206494 · Abbvie

Avycaz

Avibactam Sodium, Ceftazidime · Intravenous

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Apr 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Feb 25, 2015

Approved uses

8

Original approval plus efficacy supplements

Registered trials

64

17 Phase 3, 13 recruiting

FAERS reports

169

72 serious, 16 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 30, 2025.

AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible Gram-negative microorganisms in adult and pediatric patients (at least 31 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole ( 1.1 ) Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.4 ) 1. 1 Complicated Intra- a bdominal Infections ( cIAI ) AVYCAZ (ceftazidime and avibactam) in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adult and pediatric patients (at least 31 weeks gestational age) caused by the following susceptible gram-negative microorganisms: Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis, Enterobacter cloacae, Klebsiella oxytoca, Citrobacter freundii complex, and Pseudomonas aeruginosa . 1. 2 Complicated Urinary Tract Infections ( cUTI ), including Pyelonephritis AVYCAZ (ceftazidime and avibactam) is indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in adult and pediatric patients (at least 31 weeks gestational age) caused by the following susceptible gram-negative microorganisms: Escherichia coli , Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter freundii complex, Proteus mirabilis , and...

Mechanism: AVYCAZ is an antibacterial drug [ see Clinical Pharmacology ( 12.4 ) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 26, 2024 Supplement 12 · Efficacy · priority review LabelLetter
  • Dec 20, 2022 Supplement 11 · Efficacy · priority review LabelLetter
  • Mar 14, 2019 Supplement 6 · Efficacy · priority review LabelLetter
  • Mar 14, 2019 Supplement 5 · Efficacy · priority review LabelLetterPediatric Medical Review
  • Feb 1, 2018 Supplement 4 · Efficacy · priority review LabelLetter
  • Jan 26, 2017 Supplement 3 · Efficacy · priority review LabelLetter
  • Jun 22, 2016 Supplement 2 · Efficacy · priority review LabelLetter
  • Feb 25, 2015 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelReviewSummary Review
1 products under this application
  • AVYCAZ · AVIBACTAM SODIUM EQ 0.5GM BASE; CEFTAZIDIME 2GM/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Avibactam" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use34
  • product storage error15
  • drug resistance12
  • respiratory failure9
  • acute kidney injury8
  • hypotension7
  • mental status changes7
  • pyrexia7
  • death6
  • dyspnoea6
  • headache6
  • nausea6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201515
201622
201719
201811
201926
202014
202111
202210
20234
20248
202514
202615

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Avycaz (Ceftazidime/Avibactam)

2024 spending

$19.5M

Beneficiaries

1,123

4,263 claims

Per beneficiary

$17,394

$64.78 per unit

View as table
YearSpending
2020$6,452,941
2021$15,488,474
2022$12,650,710
2023$15,574,943
2024$19,533,400

Part B: Avycaz (Ceftazidime/Avibactam) · HCPCS J0714

2024 spending

$303K

Beneficiaries

87

351 claims

Per beneficiary

$3,485

2024 ASP limit $97.92 per unit

View as table
YearSpending
2020$745,400
2021$1,393,971
2022$498,950
2023$255,004
2024$303,195

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 109 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.